Approval · Notice of Compliance 11196 · 2010
EBIXA: Notice of Compliance 11196
Issued March 24, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11196
- Date
- March 24, 2010
- Company
- Lundbeck Canada IncSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revision of the dosing recommendations in renal impairment and creation of a Consumer Information Leaflet
- Therapeutic class
- N-methyl-D-aspartate (NMDA) receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EBIXA | Not yet assigned | — |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 10 MG per TAB